Clinical Trials Logo

Glioma, Malignant clinical trials

View clinical trials related to Glioma, Malignant.

Filter by:

NCT ID: NCT03392545 Recruiting - Glioblastoma Clinical Trials

Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)

InSituVac1
Start date: April 1, 2018
Phase: Phase 1
Study type: Interventional

The study will investigate combined radiotherapy and immunotherapy on malignant gliomas. Immune adjuvants will be injected intratumorally and systemically to induce antitumor-specific immunity after radiation induced immunological tumor cell death (ICD). With radiation, tumor cells release tumor antigens that are captured by antigen presenting dendritic cells. Immune adjuvants promote the presentation of tumor antigens and the priming of antitumor T lymphocytes. The combined treatment induces and amplifies the specific antitumor immunity in patients with malignant gliomas, prolonging survivals of patients.